Log in

Ocugen Stock Forecast, Price & News

-0.01 (-3.44 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $0.28
50-Day Range
MA: $0.32
52-Week Range
Now: $0.28
Volume2.72 million shs
Average Volume14.58 million shs
Market Capitalization$51.39 million
P/E RatioN/A
Dividend YieldN/A
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:OCGN



Sales & Book Value

Annual SalesN/A
Book Value$0.21 per share


Net Income$-20,240,000.00


Market Cap$51.39 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
-0.01 (-3.44 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OCGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ocugen (NASDAQ:OCGN) Frequently Asked Questions

How has Ocugen's stock been impacted by Coronavirus (COVID-19)?

Ocugen's stock was trading at $0.3612 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OCGN shares have decreased by 22.3% and is now trading at $0.2806.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Ocugen?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ocugen

When is Ocugen's next earnings date?

Ocugen is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Ocugen

How were Ocugen's earnings last quarter?

Ocugen (NASDAQ:OCGN) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.16. The business had revenue of $0.04 million for the quarter.
View Ocugen's earnings history

What price target have analysts set for OCGN?

3 brokers have issued 1-year price objectives for Ocugen's stock. Their forecasts range from $0.70 to $1.25. On average, they expect Ocugen's stock price to reach $0.98 in the next year. This suggests a possible upside of 250.4% from the stock's current price.
View analysts' price targets for Ocugen

Are investors shorting Ocugen?

Ocugen saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 6,110,000 shares, an increase of 35.8% from the September 15th total of 4,500,000 shares. Based on an average daily volume of 31,880,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 4.7% of the company's shares are sold short.
View Ocugen's Short Interest

Who are some of Ocugen's key competitors?

What other stocks do shareholders of Ocugen own?

Who are Ocugen's key executives?

Ocugen's management team includes the following people:
  • Dr. Shankar Musunuri Ph.D., MBA, Founder, Chairman & CEO
  • Dr. Uday B. Kompella, Founder & Director
  • Dr. Rasappa Arumugham, Chief Scientific Officer
  • Ms. Kelly A. Beck M.B.A., P.M.P., SPHR, VP of Investor Relations & Admin.
  • Dr. Daniel M. Jorgensen M.D., MPH, MBA, Chief Medical Officer

What is Ocugen's stock symbol?

Ocugen trades on the NASDAQ under the ticker symbol "OCGN."

Who are Ocugen's major shareholders?

Ocugen's stock is owned by a number of retail and institutional investors. Top institutional investors include WINTON GROUP Ltd (0.20%). Company insiders that own Ocugen stock include Howard C Draft, Junge Zhang, Kirsten Castillo, Sanjay Subramanian and Shankar Musunuri.
View institutional ownership trends for Ocugen

Which institutional investors are buying Ocugen stock?

OCGN stock was purchased by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd. Company insiders that have bought Ocugen stock in the last two years include Howard C Draft, Junge Zhang, Kirsten Castillo, Sanjay Subramanian, and Shankar Musunuri.
View insider buying and selling activity for Ocugen

How do I buy shares of Ocugen?

Shares of OCGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ocugen's stock price today?

One share of OCGN stock can currently be purchased for approximately $0.28.

How big of a company is Ocugen?

Ocugen has a market capitalization of $51.39 million. The company earns $-20,240,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Ocugen employs 14 workers across the globe.

What is Ocugen's official website?

The official website for Ocugen is ocugen.com.

How can I contact Ocugen?

Ocugen's mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The company can be reached via phone at 484-328-4701 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.